Kiadis receives $3.9M boost for blood cancer trial

06/27/2013 | Genetic Engineering & Biotechnology News

A division of the Netherlands' Ministry of Economic Affairs granted Kiadis Pharma a loan worth around $3.9 million to support midstage trials of ATIR. The drug candidate is designed to permit stem cell transplantations for blood cancer patients with partially mismatched or haploidentical donors.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Medical Officer
VANDERBILT HEALTH AFFILIATE NETWORK
Nashville, TN
National Affairs Analyst
Verisk Analytics
Jersey City, NJ
Assistant General Counsel, Regulatorya
Cardinal Health
Waukegan, IL
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA